HLA-B17 and the HLA-A1, B17 haplotype in acute myelogenous leukemia.

Abstract

Seventy-nine Caucasians with acute myelogenous leukemia (AML) were genotyped to determine whether AML, the induction of remission or patient survival were associated with particular HLA phenotypes or haplotypes. HLA-B17 and B27 were increased in AML patients over 40 years of age. Combined analysis of four independent studies indicates that HLA-B17 is significantly but weakly associated with AML, relative risk = 1.48 (.01 less than P less than .025). The A1, B17 and Aw24, Bw35 haplotypes occurred more frequently in the AML group as compared to racial and geographic controls (uncorrected P = 0.0068 and 0.0098, respectively Fisher's Exact Test). Induction of remission occurred less frequently in patients with the B17 phenotype as compared to patients lacking this antigen (P = 0.047). Patient survival was associated with remission status (P = 0.002) but was not significantly associated with particular HLA phenotypes or haplotypes. These results indicate that a gene or genes in the HLA-B region of the major histocompatibility complex can influence susceptibility to AML and also the response to chemotherapy.

• Authors: E Heise, E Parrish, R Cooper
• Journal: Tissue antigens (Tissue Antigens) Vol. 14 Issue 2 Pg. 98-104 (Aug 1979) ISSN: 0001-2815 [Print] England
• PMID: 291140 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• HLA Antigens

Topics

• Adolescent
• Adult
• Aged
• Female
• HLA Antigens (analysis)
• Haploidy
• Humans
• Leukemia, Myeloid, Acute (genetics, immunology, mortality)
• Male
• Middle Aged
• Phenotype
• Prognosis
• Prospective Studies
• Remission, Spontaneous